Kalaris Therapeutics, Inc. has been working on developing new treatments specifically targeting retinal diseases, including neovascular Age-related Macular Degeneration.
1 report, 1 independent
Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Kalaris Therapeutics, Inc. has been working on developing new treatments specifically targeting retinal diseases, including neovascular Age-related Macular Degeneration.
Coverage
Newest first; wire copies grouped- GlobeNewswireKalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered